Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The Duchenne muscular dystrophy (DMD) Video Assessment requires a caregiver to record six videos of their ambulatory child performing physical activities using a smartphone application (app). Innovative assessments that combine a performance measure, technology, and an observer require new approaches to content validation studies. This study presents a novel approach to establish the feasibility and content validity of the Video Assessment and usability of the app.
Interviews used concept elicitation and an adapted cognitive debriefing approach. Interviews were conducted with 8 clinicians who reviewed training materials prior to the interview and provided feedback on the appropriateness and usefulness of the DMD Video Assessment and the relevance of the physical activities. Four caregivers reviewed training materials and used the app to record their child performing the physical activities prior to the interview. Researchers reviewed the recordings against a checklist to identify discrepancies in caregivers’ understanding of the training materials prior to an interview. During the interview, caregivers commented on comprehension of the materials, appropriateness of the activities, and feasibility of recording the videos.
Clinicians found the DMD Video Assessment and materials appropriate and useful for assessing disease progression and treatment response. Caregivers found the activities appropriate and the training materials and app easy to understand and use. Feedback resulted in changes to the training materials, but not the activities or videotaping procedure.
Researchers used an innovative methodological approach that adapted traditional methods of content validation for the purpose of evaluating a technology-based performance measure in its totality. While future studies should be conducted with a larger, more diverse sample, these study findings add to our understanding of the content validity of the DMD Video Assessment.
Kole, R., & Krieg, A. M. (2015). Exon skipping therapy for Duchenne muscular dystrophy. Advanced Drug Delivery Reviews, 87, 104–107. https://doi.org/10.1016/j.addr.2015.05.008. CrossRefPubMed
Aartsma-Rus, A., Ginjaar, I. B., & Bushby, K. (2016). The importance of genetic diagnosis for Duchenne muscular dystrophy. Journal of Medical Genetics, 53(3), 145–151. https://doi.org/10.1136/jmedgenet-2015-103387. CrossRefPubMedPubMedCentral
Kinali, M., Arechavala-Gomeza, V., Feng, L., et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A single-blind, placebo-controlled, dose-escalation, proof-of-concept study. The Lancet Neurology, 8(10), 918–928. https://doi.org/10.1016/S1474-4422(09)70211-X. CrossRefPubMedPubMedCentral
Emery, A. E. (1991). Population frequencies of inherited neuromuscular diseases—A world survey. Neuromuscular Disorders: NMD, 1(1), 19–29. CrossRef
Allen, D. G., Whitehead, N. P., & Froehner, S. C. (2016). Absence of dystrophin disrupts skeletal muscle signaling: Roles of Ca 2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiological Reviews, 96(1), 253–305. https://doi.org/10.1152/physrev.00007.2015. CrossRefPubMed
Mayhew, A., Cano, S., Scott, E., Eagle, M., Bushby, K., & Muntoni, F. (2011). Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Developmental Medicine and Child Neurology, 53(6), 535–542. https://doi.org/10.1111/j.1469-8749.2011.03939.x. CrossRefPubMed
McDonald, C., Reha, A., Elfring, G. L., Peltz, S. W., & Spiegel, R. (2014). TP 5: Timed function tests and other physical function outcomes in Ataluren-treated patients with nonsense mutation Duchenne Muscular Dystrophy (nmDMD). Neuromuscular Disorders, 24(9), 861. CrossRef
Klingels, K., Mayhew, A. G., Mazzone, E. S., et al. (2017). Development of a patient-reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM. Developmental Medicine and Child Neurology, 59(2), 224–231. https://doi.org/10.1111/dmcn.13277. CrossRefPubMed
Landfeldt, E., Mayhew, A., Eagle, M., et al. (2015). Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT). Neuromuscular Disorders: NMD, 25(12), 937–944. https://doi.org/10.1016/j.nmd.2015.09.012. CrossRefPubMed
US Food and Drug Administration. (2009). Guidance for industry patient-reported outcome measures: Use in medical product development to support labeling claims. Silver Spring: US Food and Drug Administration.
Patrick, D. L., Burke, L. B., Gwaltney, C. J., et al. (2011). Content validity—Establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: Part 2—Assessing respondent understanding. Value in Health, 14(8), 978–988. https://doi.org/10.1016/j.jval.2011.06.013. CrossRefPubMed
Walton, M. K., Powers, J. H., Hobart, J., et al. (2015). Clinical outcome assessments: Conceptual foundation-report of the ISPOR clinical outcomes assessment—emerging good practices for outcomes research task force. Value in Health, 18(6), 741–752. https://doi.org/10.1016/j.jval.2015.08.006. CrossRefPubMedPubMedCentral
- Adapting traditional content validation methods to fit purpose: an example with a novel video assessment and training materials in Duchenne muscular dystrophy (DMD)
Michelle K. White
- Springer International Publishing